Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
203 hedge funds and large institutions have $3.37B invested in Amicus Therapeutics in 2018 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 87 increasing their positions, 57 reducing their positions, and 15 closing their positions.
147% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 15
80% more call options, than puts
Call options by funds: $137M | Put options by funds: $76.1M
53% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 57
15% more capital invested
Capital invested by funds: $2.93B → $3.37B (+$433M)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
10% more funds holding
Funds holding: 185 → 203 (+18)
3.22% less ownership
Funds ownership: 123.77% → 120.54% (-3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$41.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$41.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$34.1M |
| 4 |
PA
Perceptive Advisors
New York
|
+$32.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$31.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$68.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$62.6M |
| 3 |
Morgan Stanley
New York
|
-$58M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$49.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$41.3M |
FOLD Hedge Fund Activity: Q1 2018 in Review
203 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2018, worth a combined $3.37B — up 15% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new FOLD positions and 15 closed out — a net gain of 22 holders — while 87 added to existing stakes and 57 trimmed.
The largest buyer was Invesco, adding an estimated $41.9M. The largest seller was Fidelity Investments, cutting an estimated $68.6M.
- 203 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2018, up from 185 in Q4 2017.
- Funds reported $3.37B of Amicus Therapeutics stock for Q1 2018, up 15% quarter-over-quarter.
- 37 funds opened new Amicus Therapeutics positions in Q1 2018 and 15 closed out, a net change of +22 holders.
- The largest Amicus Therapeutics buyer in Q1 2018 was Invesco, an estimated $41.9M added.
- The largest Amicus Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $68.6M sold.
Based on aggregated 13F filings for Q1 2018.